TTKHLTCARE:NSE-TTK Healthcare Limited (INR)

COMMON STOCK | Drug Manufacturers-General | NSE

Last Closing Price

INR 570.05

Change

+14.05 (+2.53)%

Market Cap

INR 7.96B

Volume

4.00K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

TTK Healthcare Limited engages in the pharmaceutical, consumer product, medical device, protective device, and food businesses in India and internationally. The company's Pharmaceuticals segment deals in herbal and allopathic formulations in various therapeutic areas for human and veterinary uses. It also provides delivery care, female healthcare, haematinic, pain management, neurotrophic, gastro intestinal, male and female fertility, nutritional, cardiac care, derma, urinary specialties, and respiratory care products, as well as calcium supplements. Its Consumer Products segment is involved in marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, air fresheners, etc. The company's Medical Devices segment manufactures and distributes artificial heart valves; and develops orthopedic implants and instruments. Its Protective Devices segment manufactures and markets male contraceptives and other allied products. The company's Foods segment manufactures and markets food products, including potato and cereal based pellets. Its Others segment prints and publishes maps and atlases. The company was incorporated in 1958 and is headquartered in Chennai, India. TTK Healthcare Limited is a subsidiary of T T Krishnamachari & Co., Ltd.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-25 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CIPLA:NSE Cipla Limited

+20.10 (+2.55%)

INR652.30B 29.19 14.90
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-10.30 (-0.42%)

INR419.30B 33.76 18.83
GLAND:NSE Gland Pharma Limited

+36.45 (+1.53%)

INR389.30B 39.89 28.23
ABBOTINDIA:NSE Abbott India Limited

-239.05 (-1.64%)

INR310.14B 47.76 30.98
GLAXO:NSE GlaxoSmithKline Pharmaceutical..

+21.70 (+1.49%)

INR246.15B 51.09 31.79
PFIZER:NSE Pfizer Limited

+88.75 (+1.99%)

INR207.40B 41.48 25.12
SANOFI:NSE Sanofi India Limited

-10.10 (-0.12%)

INR187.90B 39.32 21.72
MARKSANS:NSE Marksans Pharma Limited

-0.05 (-0.09%)

INR22.16B 10.90 7.70
SMSPHARMA:NSE SMS Pharmaceuticals Limited

+7.85 (+6.38%)

INR10.43B 22.73 12.49
KOPRAN:NSE Kopran Limited

-1.55 (-1.25%)

INR5.34B 10.40 7.08

ETFs Containing TTKHLTCARE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.11% 73% C 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.11% 73% C 38% F
Trailing 12 Months  
Capital Gain 15.05% 64% D 32% F
Dividend Return 0.61% 40% F 33% F
Total Return 15.65% 64% D 32% F
Trailing 5 Years  
Capital Gain -33.86% 9% F 28% F
Dividend Return 2.67% 40% F 24% F
Total Return -31.19% 9% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain -12.90% 9% F 24% F
Dividend Return 0.59% 50% F 43% F
Total Return -12.31% 9% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 25.10% 64% D 78% C+
Risk Adjusted Return -49.04% 9% F 18% F
Market Capitalization 7.96B 25% F 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 21.52 83% B 47% F
Price/Book Ratio 2.94 83% B 29% F
Price / Cash Flow Ratio 40.12 42% F 12% F
EV/EBITDA 15.37 67% D+ 40% F
Management Effectiveness  
Return on Equity 12.72% 45% F 73% C
Return on Invested Capital 2.47% 25% F 36% F
Return on Assets 0.85% 18% F 38% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.83 36% F 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector